IQVIA Holdings Inc. $IQV Shares Bought by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 173.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,654 shares of the medical research company’s stock after purchasing an additional 3,585 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in IQVIA were worth $891,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Canada Pension Plan Investment Board boosted its stake in shares of IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after purchasing an additional 312,807 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after acquiring an additional 798,534 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after acquiring an additional 606,391 shares during the last quarter. American Century Companies Inc. boosted its position in shares of IQVIA by 26.8% in the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock worth $253,695,000 after acquiring an additional 304,258 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of IQVIA by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after acquiring an additional 40,699 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on IQV. Truist Financial raised their target price on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Barclays raised their target price on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their target price for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Finally, Evercore ISI raised their price target on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $234.57.

IQVIA Trading Up 0.4%

IQV opened at $218.26 on Wednesday. The firm has a market capitalization of $37.10 billion, a P/E ratio of 31.59, a P/E/G ratio of 2.39 and a beta of 1.32. The firm’s 50 day moving average is $195.48 and its 200-day moving average is $172.51. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $225.91. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.